Drug Profile
Meningococcal vaccine group B - GSK
Alternative Names: 4CMenB; Bexsero; Four component, meningococcal serogroup B vaccine (4CMenB) - GSK; GSK-3536829; GSK-3536829A; MenB; MenB+OMV NZ - GSK; Meningococcal B recombinant vaccine - GSK; Multi-component meningococcal B vaccine (Bexsero) - GSK; rMenB+OMV NZLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Norwegian Institute of Public Health; Novartis
- Developer GSK; Novartis
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Meningococcal group B infections
Most Recent Events
- 13 Sep 2022 GlaxoSmithKline completes its phase III trial for Meningococcal B infections (In adults, In adolescents, In volunteers) in USA, Australia, Finland, Turkey, Canada, Czech Republic and Estonia (NCT04502693)
- 21 Oct 2020 Pooled analysis for efficacy data from phase II, II/III trials Meningococcal group B infections (In adolescents) released by GlaxoSmithKline
- 25 Aug 2020 GlaxoSmithKline initiates a phase III trial for Meningococcal group B infections (In adolescents, In adults) (IM) (NCT04318548)